170 related articles for article (PubMed ID: 7956947)
41. Desensitization of melanoma cells to autocrine TGF-beta isoforms.
Krasagakis K; Krüger-Krasagakes S; Fimmel S; Eberle J; Thölke D; von der Ohe M; Mansmann U; Orfanos CE
J Cell Physiol; 1999 Feb; 178(2):179-87. PubMed ID: 10048582
[TBL] [Abstract][Full Text] [Related]
42. Transforming growth factor beta 1 in liver carcinogenesis: messenger RNA expression and growth effects.
Braun L; Gruppuso P; Mikumo R; Fausto N
Cell Growth Differ; 1990 Mar; 1(3):103-11. PubMed ID: 1964076
[TBL] [Abstract][Full Text] [Related]
43. Prostate carcinoma response to cytotoxic therapy: in vivo resistance.
Teicher BA; Kakeji Y; Ara G; Herbst RS; Northey D
In Vivo; 1997; 11(6):453-61. PubMed ID: 9509295
[TBL] [Abstract][Full Text] [Related]
44. Role of transforming growth factor-beta1 in prostate cancer.
Wikström P; Damber J; Bergh A
Microsc Res Tech; 2001 Feb; 52(4):411-9. PubMed ID: 11170300
[TBL] [Abstract][Full Text] [Related]
45. Transforming growth factor-beta 3 is expressed in nondividing basal epithelial cells in normal human prostate and benign prostatic hyperplasia, and is no longer detectable in prostate carcinoma.
Djonov V; Ball RK; Graf S; Mottaz AE; Arnold AM; Flanders K; Studer UE; Merz VW
Prostate; 1997 May; 31(2):103-9. PubMed ID: 9140123
[TBL] [Abstract][Full Text] [Related]
46. A proliferative effect of transforming growth factor-beta1 on a human prostate cancer cell line, TSU-Pr1.
Lamm ML; Sintich SM; Lee C
Endocrinology; 1998 Feb; 139(2):787-90. PubMed ID: 9449654
[TBL] [Abstract][Full Text] [Related]
47. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
48. In vivo real-time imaging of TGF-beta-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer.
Zhang J; Lu Y; Dai J; Yao Z; Kitazawa R; Kitazawa S; Zhao X; Hall DE; Pienta KJ; Keller ET
Prostate; 2004 Jun; 59(4):360-9. PubMed ID: 15065084
[TBL] [Abstract][Full Text] [Related]
49. Immunohistochemical expression of transforming growth factor beta 1 and nm-23 H1 antioncogene in prostate cancer: divergent correlation with clinicopathological parameters.
Stravodimos K; Constantinides C; Manousakas T; Pavlaki C; Pantazopoulos D; Giannopoulos A; Dimopoulos C
Anticancer Res; 2000; 20(5C):3823-8. PubMed ID: 11268461
[TBL] [Abstract][Full Text] [Related]
50. Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells.
Tang B; de Castro K; Barnes HE; Parks WT; Stewart L; Böttinger EP; Danielpour D; Wakefield LM
Cancer Res; 1999 Oct; 59(19):4834-42. PubMed ID: 10519393
[TBL] [Abstract][Full Text] [Related]
51. Transforming growth factor beta 1 as a biomarker for prostate cancer.
Thompson TC; Truong LD; Timme TL; Kadmon D; McCune BK; Flanders KC; Scardino PT; Park SH
J Cell Biochem Suppl; 1992; 16H():54-61. PubMed ID: 1289674
[TBL] [Abstract][Full Text] [Related]
52. Transforming growth factor beta 1 expression in benign and malignant prostatic tumors.
Glynne-Jones E; Harper ME; Goddard L; Eaton CL; Matthews PN; Griffiths K
Prostate; 1994 Oct; 25(4):210-8. PubMed ID: 7521962
[TBL] [Abstract][Full Text] [Related]
53. Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in normal and malignant human prostate.
Perry KT; Anthony CT; Steiner MS
Prostate; 1997 Oct; 33(2):133-40. PubMed ID: 9316654
[TBL] [Abstract][Full Text] [Related]
54. Glucocorticoid regulation of transforming growth factor-beta activation in urogenital sinus mesenchymal cells.
Rowley DR
Endocrinology; 1992 Jul; 131(1):471-8. PubMed ID: 1612028
[TBL] [Abstract][Full Text] [Related]
55. Effects of transforming growth factor beta 1 on the adenylyl cyclase-cAMP pathway in prostate cancer.
Steiner MS; Wand GS; Barrack ER
Growth Factors; 1994; 11(4):283-90. PubMed ID: 7779408
[TBL] [Abstract][Full Text] [Related]
56. Transforming growth factor-beta1 and prostate cancer.
Wikström P; Bergh A; Damber JE
Scand J Urol Nephrol; 2000 Apr; 34(2):85-94. PubMed ID: 10903068
[TBL] [Abstract][Full Text] [Related]
57. Prostatic ductal system in rats: tissue-specific expression and regional variation in stromal distribution of transforming growth factor-beta 1.
Nemeth JA; Sensibar JA; White RR; Zelner DJ; Kim IY; Lee C
Prostate; 1997 Sep; 33(1):64-71. PubMed ID: 9294629
[TBL] [Abstract][Full Text] [Related]
58. Intermediate filament expression and the progression of prostatic cancer as studied in the Dunning R-3327 rat prostatic carcinoma system.
Ramaekers FC; Verhagen AP; Isaacs JT; Feitz WF; Moesker O; Schaart G; Schalken JA; Vooijs GP
Prostate; 1989; 14(4):323-39. PubMed ID: 2664736
[TBL] [Abstract][Full Text] [Related]
59. Elevated transforming growth factor-beta 1 and beta 3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progression.
Merz VW; Miller GJ; Krebs T; Timme TL; Kadmon D; Park SH; Egawa S; Scardino PT; Thompson TC
Mol Endocrinol; 1991 Apr; 5(4):503-13. PubMed ID: 1922083
[TBL] [Abstract][Full Text] [Related]
60. Dog mastocytoma cells produce transforming growth factor beta 1.
Pennington DW; Lopez AR; Thomas PS; Peck C; Gold WM
J Clin Invest; 1992 Jul; 90(1):35-41. PubMed ID: 1634619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
